Abstract
The availability of antiretroviral therapy (ART) to individuals infected with HIV in many African countries has greatly increased since 2004, as result of coordinated efforts of funding agencies and individual governments in rolling out HIV care and treatment. As the numbers of individuals receiving ART rises, the long-term clinical outcomes of ART among patients on treatment, needs to be further understood. In many resource-limited countries, the data on patterns of HIV resistance to antiretroviral drugs and the effect of HIV subtype diversity on resistance remains limited. Patients’ social economic situations and deficiencies in health systems could promote non-adherence that facilitates the development of drug resistance. Here we explore available data on HIV-1 resistance to ART in Africa, in relation to the drug regimens used, HIV-1 subtype diversity and its implication on drug resistance. We specifically examine reported HIV resistance associated with treatment, transmitted resistance, and prevention of mother-to-child transmission programs. Finally, we identify specific measures both in terms of research and public health efforts to contain and prevent drug resistance development in patients on treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
UNAIDS (2010) Botswana: progress towards universal access and the declaration of commitment on HIV/AIDS. UNAIDS, Geneva
UNAIDS (2010) AIDS epidemic update. http://data.unaids.org/pub/Report/2009/JCI700EpiUpdate2009en.pdf
UNAIDS/WHO (2008) Epidemiological fact sheets on HIV and AIDS, 2008 updates. UNAIDS, Geneva
Kanki P (2009) The challenge and response in Nigeria. In: Kanki P, Marlink R (eds) A line drawn in the sand: responses to the AIDS treatment crisis in Africa. Harvard Center for Population and Development Studies, Cambridge, MA, pp 63–91
USAID (2008) Africa region: HIV/AIDS health profile. USAID
TACAID (2008) Tanzania: Country progress report. UNAIDS, Geneva
Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y et al (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368:505–510
WHO (2006) Antiviral therapy for HIV infection in adults and adolescents: recommendations for public health approach. World Health Organization, Geneva
WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents, recommendations for a public health approach
Preston BD (1997) Reverse transcriptase fidelity and HIV-1 variation. Science 275:228–229, author reply 230–221
Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242:1171–1173
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126
Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–122
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D et al (2007) Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15:119–125
Bisson GP, Frank I, Gross R, Lo Re V 3rd, Strom JB, Wang X et al (2006) Out-of-pocket costs of HAART limit HIV treatment responses in Botswana’s private sector. AIDS 20:1333–1336
Cohen GM (2007) Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries. AIDS 21(suppl 4):S81–S87
Nugent R, Pickett J, Back E (2008) Drug resistance as global health policy priority. Center for Global Development, Washington, DC
WHO (2006) The World Health report, 2006. World Health Organization, Geneva
Breen RA, Swaden L, Ballinger J, Lipman MC (2006) Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 66:2299–2308
Fonjungo PN, Dash BC, Mpoudi EN, Torimiro JN, Alemnji GA, Eno LT et al (2000) Molecular screening for HIV-1 group N and simian immunodeficiency virus cpz-like virus infections in Cameroon. AIDS 14:750–752
Jaffe HW, Schochetman G (1998) Group O human immunodeficiency virus-1 infections. Infect Dis Clin North Am 12:39–46
Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA et al (2004) Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 190:1355–1359
Hu DJ, Subbarao S, Vanichseni S, Mock PA, Ramos A, Nguyen L et al (2005) Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 19:303–308
Hemelaar J, Gouws E, Ghys PD, Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20:W13–W23
Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P et al (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367:817–824
Essex M (2009) HIV variability in Africa. In: Kanki P, Marlink R (eds) A line drawn in the sand: responses to the AIDS treatment crisis in Africa. Harvard Center for Population and Development Studies, Cambridge, MA, pp 245–258
Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41:217–224
Kantor R, Katzenstein D (2003) Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 5:25–35
Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C et al (2000) Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38:3919–3925
Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I et al (2010) Impact of HIV type 1 subtype on drug resistance mutations in nigerian patients failing first-line therapy. AIDS Res Hum Retrovir 15:1413–1420
Holguin A, Sune C, Hamy F, Soriano V, Klimkait T (2006) Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 36:264–271
Van De Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E et al (2006) The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41:352–360
Taiwo B, Chaplin B, Penugonda S, Meloni S, Akanmu S, Gashau W et al (2010) Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res 8:194–198
Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S et al (2006) High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 50:4182–4185
Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M et al (2003) A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1–F5
Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P et al (2005) Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 40:24–29
Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B et al (2007) Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 36:1009–1021
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM et al (2005) Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19:487–494
Seyler C, Adje-Toure C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D et al (2007) Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 21:1157–1164
Bussmann H, Novitsky V, Wester W, Peter T, Masupu K, Gabaitiri L et al (2005) HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother 16:103–115
Gordon M, De Oliveira T, Bishop K, Coovadia HM, Madurai L, Engelbrecht S et al (2003) Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol 77:2587–2599
Koizumi Y, Ndembi N, Miyashita M, Lwembe R, Kageyama S, Mbanya D et al (2006) Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr 43:15–22
Konings FA, Zhong P, Agwara M, Agyingi L, Zekeng L, Achkar JM et al (2004) Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retrovir 20:105–109
Vidal N, Mulanga C, Bazepeo SE, Mwamba JK, Tshimpaka J, Kashi M et al (2006) HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retrovir 22:202–206
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC et al (2002) Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med 347:385–394
Wensing AM, Van De Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E et al (2005) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192:958–966
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ulenga, N., Kanki, P.J. (2013). HIV Treatment Scale-up in Africa: The Impact of Drug Resistance. In: Lu, Y., Essex, M., Chanyasulkit, C. (eds) HIV/AIDS Treatment in Resource Poor Countries. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4520-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4520-3_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4519-7
Online ISBN: 978-1-4614-4520-3
eBook Packages: MedicineMedicine (R0)